pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,756 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda medwatch
therapy area
allOncology5005Rare Disease851Cardiology802Hematology772Immunology733Psychiatry & CNS582Pulmonology
  • AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy
    AstraZeneca said it had stopped several mid- and late-stage trials of some of its pipeline programs in the past few months, potentially limiting some of the life-cycle extensions it was hoping for.…
    Endpoints · 3mo ago↗ source
  • Opinion: Why alternative medicine can feel so much better than mainstream health care
    Modern medicine is about making people better — not necessarily making them feel good.
    STAT · 3mo ago↗ source
  • Opinion: The medical school nutrition blues
    “I don’t think anyone has the answers. But the conversation needs to start”: medical students on bringing a preventive mindset to medical education.
    STAT · 3mo ago↗ source
← prev
page 66 of 71
next →
22
fda press21
fda recalls19
571
Vaccines517
Endocrinology & Metabolism293
Ophthalmology258
Infectious Disease253
Nephrology239
  • Opinion: STAT+: Did Kennedy just stack the deck on FDA oversight of peptides?
    RFK Jr. had long signaled that he was going to do something big on peptides. Now the moment has arrived.
    STAT · 3mo ago↗ source
  • New report shows some health equity wins. Experts fear they will be short-lived
    A report released Wednesday highlights successes in reducing health disparities in U.S. states between 2022 and 2024.
    STAT · 3mo ago↗ source
  • In first meeting, federal autism committee focuses on ‘profound autism’
    The committee met for the first time since Kennedy fired most of the committee’s scientific experts and replaced them with activists and advocates.
    STAT · 3mo ago↗ source
  • STAT+: Health system CEOs get off easy at Congressional hearing on affordability
    Committee members largely blamed the other party’s health care policies for driving U.S. health care prices to levels inaccessible to many Americans.
    STAT · 3mo ago↗ source
  • STAT+: AIDS group sues Trump administration over undisclosed agreement with Gilead
    The AIDS advocacy group PrEP4All has sued the Trump administration over an undisclosed agreement with Gilead.
    STAT · 3mo ago↗ source
  • STAT+: FDA launches effort to speed up clinical trials, using AI
    Monitoring trials in real time may help shorten the time interval between trial phases.
    STAT · 3mo ago↗ source
  • Opinion: Healthcare or health care? Help STAT decide
    Should STAT use “healthcare” or “health care”? We want to hear from you.
    STAT · 3mo ago↗ source
  • FDA debuts plan to collect real-time clinical trial data
    The FDA is launching a pilot program to collect and review clinical trial data in real time, giving scientific reviewers access to the data as it flows in, the agency announced Tuesday. AstraZeneca…
    Endpoints · 3mo ago↗ source
  • The crown for healthcare admin tech is still up for grabs
    A few years in, admin tech is still reigning as the king of health tech funding. Startups using AI to tackle mundane administrative work in healthcare, such as follow-ups,
    Endpoints · 3mo ago↗ source
  • Pfizer delays patent cliff for blockbuster Vyndamax
    Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a hear…
    Endpoints · 3mo ago↗ source
  • Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development
    “For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the cloud as they occur,” writes FDA commissioner.
    STAT · 3mo ago↗ source
  • Hikma and Amarin's generic drug case heads to Supreme Court arguments
    When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications o…
    Endpoints · 3mo ago↗ source
  • Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
    The charges against Morens come after Congressional probes related to the origins of the virus that causes Covid-19.
    STAT · 3mo ago↗ source
  • Pfizer deals extend patent life for a top-selling rare disease drug
    Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have implications for others, including BridgeBio Pharma and Alnylam.
    BioPharma Dive · 3mo ago↗ source
  • Boehringer dual-acting obesity shot hits mark in Phase 3 trial
    Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
    The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
    STAT · 3mo ago↗ source
  • Rocket's PRV goes for $180M; Oruka targets $500M offering
    Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...
    Endpoints · 3mo ago↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
    The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…
    Endpoints · 3mo ago↗ source
  • Incyte claims double Phase 3 win in vitiligo, will file for approval
    Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...
    Endpoints · 3mo ago↗ source
  • FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
    Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 3mo ago↗ source
  • STAT+: Google’s clinical director on AI challenges
    In this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.
    STAT · 3mo ago↗ source